Detection of Minimal Residual Disease in Cerebro-Spinal Fluid of a Patient with Acute Myelogenous Leukemia with t(16 ; 21)(p11 ;q22) Translocation by Reverse Transcriptase-Polymerase Chain Reaction

Hideo Harigae, Masaru Kobayashi, Akio Mihara, Norimichi Watanabe

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

We describe a patient with acute myelogenous leukemia (AML) with t(16 ; 21)(p11 ; q22) translocation, whose minimal residual disease (MRD) both in cerebrospinal fluid (CSF) and bone marrow (BM) was monitored by reverse transcriptase-polymerase chain reaction (RT-PCR). A TLS/ERG-FUS fusion transcript, which is known to be expressed by t(16 ; 21)(p11 ; q22) translocation, was detectable by RT-PCR both in BM and CSF cells in the first complete remission, suggesting the existence of MRD. The disease relapsed 6 months after its onset and allogeneic peripheral blood stem cell transplantation (PBSCT) was undergone. A TLS/ERG-FUS fusion transcript became rapidly below the detection level after PBSCT. These findings suggest the usefulness of RT-PCR for the detection of MRD in CSF, which contains a limited number of cells as well as BM.

Original languageEnglish
Pages (from-to)297-302
Number of pages6
JournalTohoku Journal of Experimental Medicine
Volume183
Issue number4
DOIs
Publication statusPublished - 1997 Dec

Keywords

  • Acute myelogeous leukemia
  • Allogeneic peripheral blood stem cell transplantation
  • Minimal residual disease
  • TLS/FUS-ERG fusion transcript
  • t(16 ; 21)(p11 ; q22) translation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Detection of Minimal Residual Disease in Cerebro-Spinal Fluid of a Patient with Acute Myelogenous Leukemia with t(16 ; 21)(p11 ;q22) Translocation by Reverse Transcriptase-Polymerase Chain Reaction'. Together they form a unique fingerprint.

Cite this